Федеральные клинические рекомендации - протоколы по ведению пациентов с врожденной дисфункцией коры надпочечников в детском возрасте

Клинические рекомендации по врожденной дисфункции коры надпочечников у детей содержат краткие сведения по эпидемиологии, этиологии и патогенезу всех форм ВДКН. Особое внимание уделено диагностике дефицита 21-гидроксилазы в рамках неонатального скрининга и ведению пациентов с ранней диагностикой заболевания. Представлены подробные схемы заместительной гормональной терапии и протоколы наблюдения за пациентами разных возрастных групп. Освещены вопросы пренатальной и предимплантационной диагностики дефицита 21-гидроксилазы.

врожденная дисфункция коры надпочечников, адреногенитальный синдром, заместительная глюкокортикоидная терапия, неонатальный скрининг, пренатальная диагностика

1. Дедов И.И., Петеркова В.А. Детская эндокринология. - M.: УП-Принт, 2006.

2. Дедов И.И., Калинченко Н.Ю., Семичева Т.В., Кузнецова Э.С., Баканова Т.Д., Свердлова П.С., и др. Молекулярный анализ гена CYP21 у пациентов с врожденной дисфункцией коры надпочечников, обусловленной дефицитом 21-гидроксилазы. // Проблемы эндокринологии. - 2004. - Т. 50. - №2 - С. 3-7.

3. Дедов И.И., Орловский И.В., Карева М.А. и др. Молекулярная диагностика классических форм врожденной дисфункции коры надпочечников (дефицит стероид-21-гидроксилазы) методом аллель-специфической ПЦР. // Молекулярная медицина. - 2004. - №2 - С. 60-64.

4. Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, Gen- nari M, et al. CYP21 geno- type, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metabol 2003; 88: 5680-5688.

5. Barzon L, Maffei P, Sonino N, Pilon C, Baldazzi L, Balsamo A, et al. The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience. J Endocrinol Invest 2007; 30: 615-623.

6. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence based recommendation. J Clin Endocrinol Metabol 2009; 94: 3882-3888.

7. Burgu B, Duffy PG, Cuckow P, Ransley P, Wilcox DT. Long-term outcome of vaginal reconstruction: comparing techniques and timing. J Pediatr Urol 2007; 3: 316-320.

8. Charmandari E, Brook CG, Hindmarsh PC. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch Dis Child 2002; 86: 266-269.

9. Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metabol 2001; 86: 2701-2708.

10. Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metabol 2002; 87: 4048-4053.

11. Cornean RE, Hindmarsh PC, Brook CG Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998; 78: 261-263.

12. Fernandez-Balsells MM, Muthusamy K, Murad MH, Smushkin G, Lampropulos JF, Elamin MB, Abu Elnour NO, Elamin KB, Agrwal N, Gal- legos-Orozco JF, Erwin PJ, Montori VM. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia due to 21 hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxford) 2010; 10.1111/j.1365-2265.2010.03826.x.

13. Fiet J, Gueux B, Gourmelen M, Kuttenn F, Vexiau P, Couillin P, et al. Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. J Clin Endocrinol Metabol 1998; 66: 659-667.

14. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metabol 1997; 82: 3926-3929.

15. Hagenfeldt K, Janson PO, Holmdahl G, Falhammar H, Filipsson H, Frisén L, Thorén M, Nordenskjöld A. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23: 1607-1613.

16. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res 2001; 55: 161-171.

17. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatographytandem mass spectrometry. J Clin Endocrinol Metabol 2007; 92:2581-2589.

18. Lin-Su K, Vogiatzi MG, Marshall I, Harbison MD, Macapagal MC, Betensky B, Tansil S, New MI. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metabol 2005; 90: 3318-3325.

19. Martinez-Aguayo A, Rocha A, Rojas N, García C, Parra R, Lagos M, Valdivia L, Poggi H, Cattani A. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metabol 2007; 92:4583-4589.

20. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inter Dis Metabol 2007; 30: 585-592.

21. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GBJr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metabol 2000; 85: 1114-1120.

22. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metabol 2004; 89: 610-614.

23. Miller WL. Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metabol 1994; 78: 241-246.

24. Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Ibañez L, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183: 1468-1474.

25. New MI, Carlson A, Obeid J, Marshall I, Cabrera MS, Goseco A, et al. Prenatal diagnosis for con- genital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metabol 2001; 86: 5651-5657.

26. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metabol 1983; 57: 320-326.

27. Nordenström A, Thilén A, Hagenfeldt L, Larsson A, Wedell A. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metabol 1999; 84: 1505-1509.

28. Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1998; 81: 866-874.

29. Speiser PW, Agdere L, Ueshiba H, White PC, New MI. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 1991; 324:145-149.

30. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2010;95(9):4133-4160. doi: 10.1210/jc.2009-2631.

31. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37: 650-667.

32. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90: 584-595.

33. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, Schreuders-Bais CA, Feitz WF, Rieu PN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. J Pediatr Adolesc Gynecol 2003; 16: 289-296.

34. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1989; 101: 583-590.

35. van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM, Verkerk PH. Cutoff levels of 17-α-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metabol 2005; 90: 3904-3907.

36. Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metabol 2003; 88: 2993-2998.

37. Völkl TM, Simm D, Dötsch J, Rascher W, Dörr HG. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metabol 2006; 91: 4888-4895.

38. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrinol Rev 2000; 21: 245-291.